01-08-2003
Phase II study of XR5000 (DACA), an inhibitor of topoisomerase I and II, administered as a 120-h infusion in patients with advanced ovarian cancer*
Published in: Investigational New Drugs | Issue 3/2003
Login to get access01-08-2003
Published in: Investigational New Drugs | Issue 3/2003
Login to get access